Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells

Immunotherapy approaches currently make their way into the clinics to improve the outcome of standard radiochemotherapy (RCT). The programed cell death receptor ligand 1 (PD-L1) is one possible target that, upon blockade, allows T cell-dependent antitumor immune responses to be executed. To date, it...

Descripción completa

Detalles Bibliográficos
Autores principales: Derer, Anja, Spiljar, Martina, Bäumler, Monika, Hecht, Markus, Fietkau, Rainer, Frey, Benjamin, Gaipl, Udo S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2016
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5177615/
https://www.ncbi.nlm.nih.gov/pubmed/28066420
http://dx.doi.org/10.3389/fimmu.2016.00610

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5177615/
https://www.ncbi.nlm.nih.gov/pubmed/28066420
http://dx.doi.org/10.3389/fimmu.2016.00610

Ejemplares similares